...
bcrx-img

BioCryst Pharmaceuticals Inc, Common Stock

BCRX

NSQ

$7.78

+$0.21

(2.77%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.57B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.47M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.89
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.03 L
$8.88 H
$7.78

About BioCryst Pharmaceuticals Inc, Common Stock

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBCRXSectorS&P500
1-Week Return4.29%-0.94%-2.6%
1-Month Return7.02%-5.08%-1.08%
3-Month Return-0.13%-10.62%3.45%
6-Month Return24.08%-6.18%8.57%
1-Year Return27.96%1.98%24.3%
3-Year Return-44.11%-0.93%25.58%
5-Year Return153.42%33.84%84.07%
10-Year Return-29.72%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue48.84M17.81M157.17M270.83M331.41M[{"date":"2019-12-31","value":14.74,"profit":true},{"date":"2020-12-31","value":5.37,"profit":true},{"date":"2021-12-31","value":47.42,"profit":true},{"date":"2022-12-31","value":81.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue4.10M1.68M7.26M6.59M4.66M[{"date":"2019-12-31","value":56.46,"profit":true},{"date":"2020-12-31","value":23.07,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.78,"profit":true},{"date":"2023-12-31","value":64.17,"profit":true}]
Gross Profit44.73M16.14M149.91M264.23M326.75M[{"date":"2019-12-31","value":13.69,"profit":true},{"date":"2020-12-31","value":4.94,"profit":true},{"date":"2021-12-31","value":45.88,"profit":true},{"date":"2022-12-31","value":80.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin91.60%90.59%95.38%97.57%98.59%[{"date":"2019-12-31","value":92.91,"profit":true},{"date":"2020-12-31","value":91.88,"profit":true},{"date":"2021-12-31","value":96.74,"profit":true},{"date":"2022-12-31","value":98.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses144.19M190.89M327.63M412.67M430.46M[{"date":"2019-12-31","value":33.5,"profit":true},{"date":"2020-12-31","value":44.35,"profit":true},{"date":"2021-12-31","value":76.11,"profit":true},{"date":"2022-12-31","value":95.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(99.45M)(174.76M)(177.72M)(148.44M)(103.71M)[{"date":"2019-12-31","value":-9945500000,"profit":false},{"date":"2020-12-31","value":-17475700000,"profit":false},{"date":"2021-12-31","value":-17772000000,"profit":false},{"date":"2022-12-31","value":-14843500000,"profit":false},{"date":"2023-12-31","value":-10370900000,"profit":false}]
Total Non-Operating Income/Expense(19.40M)(13.14M)(63.32M)(189.91M)(218.62M)[{"date":"2019-12-31","value":-1940100000,"profit":false},{"date":"2020-12-31","value":-1313800000,"profit":false},{"date":"2021-12-31","value":-6332100000,"profit":false},{"date":"2022-12-31","value":-18991300000,"profit":false},{"date":"2023-12-31","value":-21861800000,"profit":false}]
Pre-Tax Income(108.90M)(182.81M)(181.81M)(244.38M)(226.23M)[{"date":"2019-12-31","value":-10889700000,"profit":false},{"date":"2020-12-31","value":-18281400000,"profit":false},{"date":"2021-12-31","value":-18180900000,"profit":false},{"date":"2022-12-31","value":-24438400000,"profit":false},{"date":"2023-12-31","value":-22622900000,"profit":false}]
Income Taxes11.17M13.75M2.25M2.73M310.00K[{"date":"2019-12-31","value":81.2,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":16.38,"profit":true},{"date":"2022-12-31","value":19.87,"profit":true},{"date":"2023-12-31","value":2.25,"profit":true}]
Income After Taxes(120.06M)(196.57M)(184.06M)(247.12M)(226.54M)[{"date":"2019-12-31","value":-12006500000,"profit":false},{"date":"2020-12-31","value":-19656700000,"profit":false},{"date":"2021-12-31","value":-18406200000,"profit":false},{"date":"2022-12-31","value":-24711700000,"profit":false},{"date":"2023-12-31","value":-22653900000,"profit":false}]
Income From Continuous Operations(108.90M)(192.23M)(184.06M)(247.12M)(236.35M)[{"date":"2019-12-31","value":-10889700000,"profit":false},{"date":"2020-12-31","value":-19223400000,"profit":false},{"date":"2021-12-31","value":-18406200000,"profit":false},{"date":"2022-12-31","value":-24711700000,"profit":false},{"date":"2023-12-31","value":-23634900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(120.06M)(196.57M)(184.06M)(247.12M)(226.54M)[{"date":"2019-12-31","value":-12006500000,"profit":false},{"date":"2020-12-31","value":-19656700000,"profit":false},{"date":"2021-12-31","value":-18406200000,"profit":false},{"date":"2022-12-31","value":-24711700000,"profit":false},{"date":"2023-12-31","value":-22653900000,"profit":false}]
EPS (Diluted)(0.98)(1.08)(1.03)(1.33)(0.99)[{"date":"2019-12-31","value":-98,"profit":false},{"date":"2020-12-31","value":-108,"profit":false},{"date":"2021-12-31","value":-103,"profit":false},{"date":"2022-12-31","value":-133,"profit":false},{"date":"2023-12-31","value":-99,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BCRX
Cash Ratio 2.15
Current Ratio 2.78
Quick Ratio 2.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BCRX
ROA (LTM) -4.25%
ROE (LTM) -1925.37%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BCRX
Debt Ratio Lower is generally better. Negative is bad. 1.95
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BCRX
Trailing PE NM
Forward PE NM
P/S (TTM) 3.80
P/B 56.59
Price/FCF 192
EV/R 4.96
EV/Ebitda NM
PEG NM

FAQs

What is BioCryst Pharmaceuticals Inc share price today?

BioCryst Pharmaceuticals Inc (BCRX) share price today is $7.78

Can Indians buy BioCryst Pharmaceuticals Inc shares?

Yes, Indians can buy shares of BioCryst Pharmaceuticals Inc (BCRX) on Vested. To buy BioCryst Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BioCryst Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of BioCryst Pharmaceuticals Inc (BCRX) via the Vested app. You can start investing in BioCryst Pharmaceuticals Inc (BCRX) with a minimum investment of $1.

How to invest in BioCryst Pharmaceuticals Inc shares from India?

You can invest in shares of BioCryst Pharmaceuticals Inc (BCRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in BCRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BioCryst Pharmaceuticals Inc shares
What is BioCryst Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of BioCryst Pharmaceuticals Inc (BCRX) is $8.88. The 52-week low price of BioCryst Pharmaceuticals Inc (BCRX) is $4.03.

What is BioCryst Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of BioCryst Pharmaceuticals Inc (BCRX) is

What is BioCryst Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BioCryst Pharmaceuticals Inc (BCRX) is 56.59

What is BioCryst Pharmaceuticals Inc dividend yield?

The dividend yield of BioCryst Pharmaceuticals Inc (BCRX) is 0.00%

What is the Market Cap of BioCryst Pharmaceuticals Inc?

The market capitalization of BioCryst Pharmaceuticals Inc (BCRX) is $1.57B

What is BioCryst Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of BioCryst Pharmaceuticals Inc is BCRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top